Sökning: onr:"swepub:oai:DiVA.org:uu-498008" >
Finerenone in Patie...
-
Rossing, Peter
(författare)
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment : The FIDELITY Analysis.
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-08-15
-
American Diabetes Association,2022
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-498008
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498008URI
-
https://doi.org/10.2337/dc22-0294DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies.RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes.RESULTS: Among 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment.CONCLUSIONS: Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Anker, Stefan D
(författare)
-
Filippatos, Gerasimos
(författare)
-
Pitt, Bertram
(författare)
-
Ruilope, Luis M
(författare)
-
Birkenfeld, Andreas L
(författare)
-
McGill, Janet B
(författare)
-
Rosas, Sylvia E
(författare)
-
Joseph, Amer
(författare)
-
Gebel, Martin
(författare)
-
Roberts, Luke
(författare)
-
Scheerer, Markus F
(författare)
-
Bakris, George L
(författare)
-
Agarwal, Rajiv
(författare)
Sammanhörande titlar
-
Ingår i:Diabetes Care: American Diabetes Association45:12, s. 2991-29980149-59921935-5548
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rossing, Peter
-
Anker, Stefan D
-
Filippatos, Gera ...
-
Pitt, Bertram
-
Ruilope, Luis M
-
Birkenfeld, Andr ...
-
visa fler...
-
McGill, Janet B
-
Rosas, Sylvia E
-
Joseph, Amer
-
Gebel, Martin
-
Roberts, Luke
-
Scheerer, Markus ...
-
Bakris, George L
-
Agarwal, Rajiv
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Diabetes Care
- Av lärosätet
-
Uppsala universitet